Evidence map›Paper›PMID 27220820›Full record

ArticlePrion2016

The Priority position paper: Protecting Europe's food chain from prions.

Jesús R Requena, Krister Kristensson, Carsten Korth, Chiara Zurzolo, Marion Simmons, Patricia Aguilar-Calvo, Adriano Aguzzi, Olivier Andreoletti, Sylvie L Benestad, Reinhard Böhm and 26 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in Prion, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Animal prion diseases: the risks to human health.Brain pathology (Zurich, Switzerland) · 2019
    Review
  2. Article
  3. The Structure of PrPPathogens (Basel, Switzerland) · 2018
    Review
  4. Article
  5. Bovine spongiform encephalopathy (BSE) cases born after the total feed ban.EFSA journal. European Food Safety Authority · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 12 countries.

Jesús R Requenaa CIMUS Biomedical Research Institute, University of Santiago de Compostela , Santiago de Compostela , Spain ;
Krister Kristenssonb Karolinska Institute , Stockholm , Sweden ;
Carsten Korthc University of Düsseldorf , Düsseldorf , Germany ;
Chiara Zurzolod Institut Pasteur , Paris , France ;
Marion Simmonse APHA , Weybridge , UK ;
Patricia Aguilar-Calvof CISA, INIA , Madrid , Spain ;
Adriano Aguzzig University of Zürich , Zürich , Switzerland ;
Olivier Andreolettih ENVT-INRA , Toulouse , France ;
Sylvie L Benestadi Norwegian Veterinary Institute , Oslo , Norway ;
Reinhard Böhmj University of Hohenheim , Stuttgart , Germany ;
Karen Brownk University of Edinburgh , Edinburgh , UK ;
Byron Calgual University of Barcelona , Barcelona , Spain ;
José Antonio Del Ríom IBEC , Barcelona , Spain ;
Juan Carlos Espinosaf CISA, INIA , Madrid , Spain ;
Rosina Gironesl University of Barcelona , Barcelona , Spain ;
Sue Godsaven Netherlands Cancer Institute , Amsterdam , The Netherlands ;
Ludwig E Hoelzlej University of Hohenheim , Stuttgart , Germany ;
Michael R Knittlero Friedrich Löffler Institut , Insel Reims , Germany ;
Franziska Kuhnp Prionics , Zürich , Switzerland ;
Giuseppe Legnameq SISSA , Trieste , Italy ;
Paul Laevenr University of Maastricht , Maastricht , The Netherlands ;
Neil Mabbottk University of Edinburgh , Edinburgh , UK ;
Eva Mitrovas Medical University of Slovakia , Bratislava , Slovakia ;
Andreas Müller-Schiffmannc University of Düsseldorf , Düsseldorf , Germany ;
Mario Nuvoloneg University of Zürich , Zürich , Switzerland ;
Peter J Peterst The Maastricht Multimodal Molecular Imaging Institute, University of Maastricht , Maastricht , The Netherlands ;
Alex Raeberp Prionics , Zürich , Switzerland ;
Klaus Rothu SMP GmbH , Tübingen , Germany ;
Matthias Schmitzv Universitätmedizin Göttingen , Göttingen , Germany ;
Björn Schroederp Prionics , Zürich , Switzerland ;
Tiziana Sonatig University of Zürich , Zürich , Switzerland ;
Lothar Stitzo Friedrich Löffler Institut , Insel Reims , Germany ;
Albert Taraboulosw The Hebrew University , Jerusalem ;
Juan María Torresf CISA, INIA , Madrid , Spain ;
Zheng-Xin Yanu SMP GmbH , Tübingen , Germany ;
Inga Zerrv Universitätmedizin Göttingen , Göttingen , Germany ;
The Geneva Association · CHUniversity of Zurich · CHCenter for International Forestry Research · IDFriedrich-Loeffler-Institut · DEHeinrich Heine University Düsseldorf · DEMaastricht University · NLUniversitat de Barcelona · ESUniversitätsmedizin Göttingen · DEUniversity of Edinburgh · GBUniversity of Hohenheim · DEBernstein Center for Computational Neuroscience Tübingen · DEGénétique Physiologie et Systèmes d'Elevage · FRHebrew University of Jerusalem · ILIngenieria Y Economia Del Transporte · ESInstitute for Bioengineering of Catalonia · ESInstitut Pasteur · FRKarolinska Institutet · SENorwegian Veterinary Institute · NOScuola Internazionale Superiore di Studi Avanzati · ITSlovak Medical University · SK

Funding

Biotechnology and Biological Sciences Research Council BBS/E/D/20251967Biotechnology and Biological Sciences Research Council BBS/E/D/20251968
6 · The paper itself

Abstract

Bovine spongiform encephalopathy (BSE) created a global European crisis in the 1980s and 90s, with very serious health and economic implications. Classical BSE now appears to be under control, to a great extent as a result of a global research effort that identified the sources of prions in meat and bone meal (MBM) and developed new animal-testing tools that guided policy. Priority ( www.prionpriority.eu ) was a European Union (EU) Framework Program 7 (FP7)-funded project through which 21 European research institutions and small and medium enterprises (SMEs) joined efforts between 2009 and 2014, to conduct coordinated basic and applied research on prions and prion diseases. At the end of the project, the Priority consortium drafted a position paper ( www.prionpriority.eu/Priority position paper) with its main conclusions. In the present opinion paper, we summarize these conclusions. With respect to the issue of re-introducing ruminant protein into the feed-chain, our opinion is that sustaining an absolute ban on feeding ruminant protein to ruminants is essential. In particular, the spread and impact of non-classical forms of scrapie and BSE in ruminants is not fully understood and the risks cannot be estimated. Atypical prion agents will probably continue to represent the dominant form of prion diseases in the near future in Europe. Atypical L-type BSE has clear zoonotic potential, as demonstrated in experimental models. Similarly, there are now data indicating that the atypical scrapie agent can cross various species barriers. More epidemiological data from large cohorts are necessary to reach any conclusion on the impact of its transmissibility on public health. Re-evaluations of safety precautions may become necessary depending on the outcome of these studies. Intensified searching for molecular determinants of the species barrier is recommended, since this barrier is key for important policy areas and risk assessment. Understanding the structural basis for strains and the basis for adaptation of a strain to a new host will require continued fundamental research, also needed to understand mechanisms of prion transmission, replication and how they cause nervous system dysfunction and death. Early detection of prion infection, ideally at a preclinical stage, also remains crucial for development of effective treatment strategies.

Indexed as

Food ChainAnimal FeedAnimalsCattleEarly DiagnosisEncephalopathy, Bovine SpongiformEuropeHumansPrion DiseasesPrionsScrapiePrionsatypical BSEatypical scrapieBSECJDprionscrapie

Identifiers

PMID27220820
PMCPMC4981192
OpenAlexW2397845161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.